How should Perinorm (perindopril) be dosed and monitored in a maintenance hemodialysis patient with hypertension, and what alternatives are available if ACE‑inhibitor intolerance occurs?

Perindopril (Perinorm) in Maintenance Hemodialysis Patients

Perindopril should be initiated at 2 mg once daily immediately after hemodialysis sessions in hypertensive dialysis patients, as more than 50% of the active metabolite perindoprilat is removed during each dialysis session. 1

Dosing Strategy

• Start with 2 mg perindopril administered immediately post-dialysis to avoid intradialytic hypotension, as hemodialysis removes >50% of circulating perindoprilat with a dialysis clearance of 62-72 mL/min. 1

• Titrate cautiously to a maximum of 4 mg once daily based on blood pressure response and tolerance, recognizing that perindoprilat accumulates significantly in dialysis patients with a mean accumulation ratio of 3.5 after one month of therapy. 1, 2

• Steady-state concentrations are reached within 3-5 hemodialysis sessions, with peak perindoprilat levels increasing from 10.2 ng/mL after the first dose to 26.8 ng/mL at steady state. 1, 2

Pharmacokinetic Considerations

• Perindoprilat renal clearance correlates strongly with creatinine clearance (r=0.87), and the serum accumulation ratio increases dramatically from 1.81 in mild renal failure to 5.35 in severe renal failure requiring dialysis. 2

• The elimination half-life and renal clearance of perindoprilat remain unchanged with chronic administration, but total drug exposure (AUC) increases substantially with worsening renal function. 2, 3

• Perindopril itself (the prodrug) shows no pharmacokinetic alterations in renal failure, as only the active metabolite perindoprilat accumulates. 2

Monitoring Requirements

• Measure blood pressure pre-dialysis targeting <140/90 mmHg and post-dialysis targeting <130/80 mmHg to minimize left ventricular hypertrophy and cardiovascular mortality. 4, 5, 6

• Monitor serum potassium closely, as ACE inhibitors increase hyperkalemia risk in dialysis patients who already have impaired potassium excretion. 4, 5

• Check serum creatinine at baseline and periodically, though perindopril does not typically worsen residual renal function in stable dialysis patients. 2, 3

• Assess for symptomatic intradialytic hypotension, which may necessitate dose reduction or timing adjustment, particularly in patients with poor cardiac reserve. 4, 5

Efficacy and Safety

• Perindopril provides sustained ACE inhibition for >24 hours even in dialysis patients, with trough/peak ratios >50% and maximal ACE inhibition occurring 4-6 hours post-dose. 7, 8

• The drug is well-tolerated in dialysis populations, with stable serum creatinine and electrolytes in most patients during 12-week trials. 3

• Cough is the most common adverse event (as with all ACE inhibitors) and the most frequent reason for discontinuation. 7

Combination Therapy

• If blood pressure remains uncontrolled on perindopril monotherapy, add a long-acting dihydropyridine calcium channel blocker (amlodipine) as second-line, as calcium channel blockers are associated with decreased cardiovascular mortality in dialysis patients. 4, 6

• A fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination can be used in non-anuric dialysis patients with residual urine output, though most maintenance hemodialysis patients are anuric and derive minimal benefit from diuretics. 3

• Add carvedilol (starting 3.125 mg twice daily) as third-line therapy if the patient has coronary artery disease, prior myocardial infarction, or heart failure, as beta-blockers reduce mortality in these dialysis subgroups. 9

Alternatives for ACE Inhibitor Intolerance

• Switch to an angiotensin receptor blocker (ARB) such as valsartan if the patient develops intolerable cough or angioedema, as ARBs provide similar renoprotection and cardiovascular benefits without the bradykinin-mediated side effects. 4

• Choose non-dialyzable ACE inhibitors (benazepril, fosinopril) over dialyzable ones (enalapril, ramipril) if switching within the ACE inhibitor class, to maintain more consistent drug levels across dialysis sessions. 4, 6

Critical Pitfalls to Avoid

• Never administer perindopril before dialysis, as the subsequent removal of >50% of active drug during the session will result in inadequate blood pressure control and wasted medication. 1

• Do not escalate antihypertensive therapy before optimizing dry weight, as volume overload is the predominant cause of hypertension in dialysis patients and premature drug intensification leads to ineffective polypharmacy. 4, 6

• Avoid combining perindopril with potassium-sparing diuretics or potassium supplements due to the high risk of life-threatening hyperkalemia in dialysis patients with minimal residual renal function. 4

• Do not use perindopril in patients with bilateral renal artery stenosis or solitary functioning kidney with renal artery stenosis, as ACE inhibition can precipitate acute kidney injury even in dialysis-dependent patients with residual function. 4